Wilmington Savings Fund Society FSB Takes Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

Wilmington Savings Fund Society FSB purchased a new position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 1,489 shares of the biopharmaceutical company’s stock, valued at approximately $83,000.

Several other large investors have also recently added to or reduced their stakes in RARE. nVerses Capital LLC purchased a new stake in shares of Ultragenyx Pharmaceutical during the second quarter valued at approximately $33,000. UMB Bank n.a. grew its holdings in Ultragenyx Pharmaceutical by 58.1% during the 2nd quarter. UMB Bank n.a. now owns 958 shares of the biopharmaceutical company’s stock valued at $39,000 after purchasing an additional 352 shares in the last quarter. True Wealth Design LLC purchased a new stake in Ultragenyx Pharmaceutical during the 3rd quarter worth $43,000. Values First Advisors Inc. acquired a new position in Ultragenyx Pharmaceutical in the 3rd quarter worth $56,000. Finally, Nomura Asset Management Co. Ltd. purchased a new position in Ultragenyx Pharmaceutical in the 3rd quarter valued at about $93,000. 97.67% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts have recently issued reports on RARE shares. Wells Fargo & Company lifted their target price on Ultragenyx Pharmaceutical from $75.00 to $88.00 and gave the stock an “overweight” rating in a research report on Friday. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $77.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, November 6th. TD Cowen raised their price target on shares of Ultragenyx Pharmaceutical from $61.00 to $73.00 and gave the stock a “buy” rating in a research report on Monday, October 21st. HC Wainwright upped their price target on shares of Ultragenyx Pharmaceutical from $82.00 to $95.00 and gave the company a “buy” rating in a report on Wednesday, November 6th. Finally, Canaccord Genuity Group reissued a “buy” rating and set a $121.00 price objective on shares of Ultragenyx Pharmaceutical in a report on Tuesday, November 12th. One research analyst has rated the stock with a hold rating and twelve have given a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $88.46.

Insider Activity at Ultragenyx Pharmaceutical

In other news, CEO Emil D. Kakkis sold 8,273 shares of the company’s stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $50.00, for a total value of $413,650.00. Following the completion of the sale, the chief executive officer now owns 2,195,712 shares in the company, valued at $109,785,600. This represents a 0.38 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CFO Howard Horn sold 7,465 shares of Ultragenyx Pharmaceutical stock in a transaction that occurred on Thursday, October 10th. The stock was sold at an average price of $52.76, for a total transaction of $393,853.40. Following the completion of the transaction, the chief financial officer now directly owns 92,301 shares in the company, valued at $4,869,800.76. This represents a 7.48 % decrease in their position. The disclosure for this sale can be found here. 5.80% of the stock is owned by insiders.

Ultragenyx Pharmaceutical Stock Up 1.7 %

Shares of RARE stock opened at $44.22 on Friday. The company has a market cap of $4.08 billion, a P/E ratio of -6.83 and a beta of 0.56. The business has a 50 day moving average of $49.53 and a two-hundred day moving average of $49.25. Ultragenyx Pharmaceutical Inc. has a 52 week low of $37.02 and a 52 week high of $60.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its quarterly earnings data on Tuesday, November 5th. The biopharmaceutical company reported ($1.40) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.45) by $0.05. Ultragenyx Pharmaceutical had a negative return on equity of 187.12% and a negative net margin of 106.93%. The business had revenue of $139.49 million during the quarter, compared to analyst estimates of $135.28 million. During the same quarter in the previous year, the firm posted ($2.23) EPS. The business’s revenue for the quarter was up 42.3% compared to the same quarter last year. Analysts expect that Ultragenyx Pharmaceutical Inc. will post -6.2 EPS for the current fiscal year.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.